Bluejay Diagnostics, Inc.

Stage 4 · Declining · week 14

As of Oct 22, 2026, Bluejay Diagnostics is in Stage 4, the downtrend phase, now in week 14 (since Jul 20, 2026). It closed at $0.63, 93.6% below its 52-week high and below its 200-day average, which is falling.

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. More about the company

$0.63

-6.84% today

$2.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BJDX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 79w

S4 26w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 5w → S4 79w → S1 2w → S4 26w → S1 8w → S4 26w → S1 7w → S4 14w current

Total tracked: 166 weeks across 8 stage runs.

BJDX among Medical Devices121st of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…121	BJDXBluejay Diagnostics, Inc.	Stage 4 · wk 14	6	−35.1%

vs 52W High

-93.6%

$0.63 lo$9.76 hi

93.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 14

1w13w26w

Week 14, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-67.0%

200 DMA: $1.91 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.02x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-35.1%

-38.9%

-67.9%

YTD

-76.0%

-93.9%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 14 · Vol 0.02x

2026-10-21S4

Wk 14 · Vol 0.02x

2026-10-20S4

Wk 14 · Vol 0.03x

2026-10-19S4

Wk 13 · Vol 0.04x

2026-10-16S4

Wk 13 · Vol 0.04x

2026-10-15S4

Wk 13 · Vol 0.02x

2026-10-14S4

Wk 13 · Vol 0.02x

2026-10-13S4

Wk 13 · Vol 0.08x

2026-10-12S4

Wk 12 · Vol 0.03x

2026-10-09S4

Wk 12 · Vol 0.02x

2026-10-08S4

Wk 12 · Vol 0.02x

2026-10-07S4

Wk 12 · Vol 0.06x

Moving averages & range

50 DMA

$0.87

200 DMA

$1.91

52W High

$9.76

52W Low

$0.63

5D Low

$0.63

Resistance levels (recent highs)

20d High

$0.96

60d High

$1.24

120d High

$5.30

250d High

$9.24

Next resistance

+52.6%

to 20d High

ROE

-98.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.1

Bluejay Diagnostics: quick answers

What stage is Bluejay Diagnostics in?

As of Oct 22, 2026, Bluejay Diagnostics (BJDX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 20, 2026 and is in week 14. What the four stages mean

Is Bluejay Diagnostics in an uptrend?

No. Bluejay Diagnostics is in a Stage 4 downtrend. It trades 67.0% below its 200-day average, which is falling.

How far is Bluejay Diagnostics from its 52-week high?

Bluejay Diagnostics closed at $0.63 on Oct 22, 2026, 93.6% below its 52-week high of $9.76. Its 52-week low is $0.63.

How has Bluejay Diagnostics performed over the past year?

As of Oct 22, 2026, Bluejay Diagnostics is down 93.9% over the past year and down 76.0% so far in 2026.

Which sector and industry is Bluejay Diagnostics in?

Bluejay Diagnostics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.